ICAM1 and type 2 diabetes mellitus: The consistency of LST1-mediated communication in both T2DM and ccRCC—particularly through MHC-I, TGF-β, CXCL, and ICAM1 pathways (44–46)—supports a unified immunological bridge between metabolic dysregulation and tumor progression.